Tenon Medical announced that it has completed the first clinical procedures using its new SImmetry+ SI Joint Fusion System on December 4, 2025. The procedures were performed at leading spine centers in Florida, Arizona, Ohio, and Texas and employed 3D‑printed titanium implants, a joint decorticator, and a streamlined bone‑graft delivery system.
The milestone marks a significant expansion of Tenon’s product line beyond its flagship Catamaran system. By adding SImmetry+, the company now offers surgeons a lateral‑approach option that complements the existing inferior‑posterior Catamaran platform, broadening its reach across primary, revision, and adjunctive sacro‑iliac joint fusion procedures. The additional product line is expected to accelerate market adoption and generate new revenue streams as the system moves toward full commercial launch.
Tenon’s Q3 2025 financial results provide context for the launch. Revenue rose to $1.17 million, up 32% from $0.887 million in Q3 2024, while the company posted a net loss of $3.3 million. The firm also completed a $2.85 million private‑placement financing in November 2025 to support product development and commercialization efforts.
Clinical data from the EvoluSIon study support the system’s effectiveness: 68.7% of patients achieved radiographic fusion at 12 months, and opioid use fell by 57.1% compared with pre‑operative levels. These outcomes reinforce the company’s claim that SImmetry+ can deliver durable results while reducing post‑operative pain and medication dependence.
Steve Foster, President and CEO, said the first successful clinical use of SImmetry+ “represents another meaningful milestone in Tenon’s mission to advance sacro‑pelvic fusion options for physicians and their patients.” He added that ongoing feedback from physician advisors will guide further refinements and that the system’s early clinical success positions Tenon to strengthen its growing sacro‑pelvic portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.